doi:10.1126/science.adn4128
[DOI] [PubMed] [Google Scholar] 108.Eisenberg D.M., Cole A., Maile E.J., Salt M., Armstrong E., Broad Leib E., Findley T., Massa J., Albin J., Alston M., et al
At 2 years, the probabilities of a net benefit for 10% weight loss were: 0.96 for semaglutide
Concerns the FDA has flagged for this category generally - not specific to VivioMD - include: Dosing errors and confusion between milliliters, milligrams, and units in compounded injectable semaglutide Products sold as "semaglutide" that may actually contain salt forms such as semaglutide sodium or semaglutide acetate, which differ from the FDA-approved active ingredient and haven't been evaluated for safety or effectiveness Improper storage and shipping conditions for compounded injectables Fraudulent labels and doses beyond approved-label schedules Underreported adverse events across the compounded-GLP-1 category The FDA recommends that compounded drugs be used only for patients whose medical needs cannot be met by an FDA-approved drug - not as a default lower-cost substitute